Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase III Study of Selumetinib NSC 748727, IND 77782 or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas LGGs Lacking BRAFV600E or IDH1 Mutations
Study Type: Treatment
Phase: III
NCTID: NCT04576117
Principal Investigator:
Keith August
A Phase III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
Study Type: Treatment
Phase: III
NCTID: NCT02176967
Principal Investigator:
Keith August
Phase II Trial of Response Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors
Study Type: Treatment
Phase: II
NCTID: NCT01602666
Principal Investigator:
Prospective Phase II Study of Cytochrome C Oxidase Activity as a Novel Biomarker In Subjects With Newly Diagnosed Primary Glioblastoma Multiforme
A Phase 2 Study of Veliparib ABT-888 and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma HGG without H3 K27M or BRAFV600 Mutations
Study Type: Treatment
Phase: II
NCTID: NCT03581292
Principal Investigator:
Kevin Ginn
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib NSC 748727 in Newly Diagnosed or Previously Untreated Low-Grade Glioma LGG Not Associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 NF1
Study Type: Treatment
Phase: III
NCTID: NCT04166409
Principal Investigator:
Keith August
Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG
Study Type: Treatment
Phase: II
NCTID: NCT02684058
Principal Investigator:
Kevin Ginn
A Phase III Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy SRT versus Surgically Targeted Radiation Therapy STaRT with Gamma Tile for Treatment of Newly Diagnosed Metastatic Brain Tumors.
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
Study Type: Treatment
Phase: II
NCTID: NCT04696029
Principal Investigator:
Kevin Ginn